A.D.A.M. Innovations Co. , Japan’s leading AI-driven genomics company, announced the release of three new first-of-their-kind cancer prediction models for its GeneLife GeneAI Forecast platform: breast cancer (women), prostate cancer (men), and pancreatic cancer (unisex), developed using the largest Japanese population genetic database built by the company over 22 years of operation, improving relevance compared with western-derived tools.

Health Technology Insights: Alleva Earns ONC Certification, SOC 2, and HIPAA Compliance

With these three additional cancer models, GeneAI Forecast, supported by Japan’s largest commercial genomic population database, now offers a total of 11 unique predictive models for diseases with rising mortality. The release of these models advances GeneLife GeneAI Forecast’s mission to deliver personalized, prevention-focused health insights for the Japanese and broader East Asian population.

Health Technology Insights: Healgen Highlights Rapid Check Test for COVID-19 and Flu Season

GeneAI Forecast uses A.D.A.M. Innovations’ extensive genomic database, built from 2.9 million completed tests, and combines genetic data with lifestyle factors such as BMI, smoking, alcohol consumption, and several other biomarkers.

This dynamic system provides users a personalized baseline risk and illustrates how lifestyle modifications can impact their long-term health. High-risk individuals can use these insights to optimize their lifestyle choices, reduce disease onset risk, or support early detection.

The three new models join existing predictive forecasts for stroke, myocardial infarction, type 2 diabetes, hypertension, chronic kidney disease, lung cancer, stomach cancer, and colorectal cancer.

GeneLife consumers can access the full line of Gene AI Forecast features through the Genesis CONNECT and WGS CONNECT subscription plans.

Designed for Japanese and East Asian Populations

“These new cancer models reflect our commitment to bringing AI-driven, personalized prevention into everyday life,” said Michel Mommejat, President of A.D.A.M. Innovations. “We aim to help individuals understand their risks and support a more proactive approach to early prevention and intervention, leading to long-term health and longevity.”

Health Technology Insights: FluidAI Medical Announces an Acquisition Deal With Emmetros Limited

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com

Source- GlobeNewswire